Ardelyx (ARDX)

• Market cap: $1.1B
• 1 day: 1.31%
• 5 days: -2.93%
• 1 month: -11.62%
• 3 months: -21.75%
• 6 months: -25.76%
• Year to date: -23.31%
• 1 year: -28.28%
• 5 years: -41.49%
• 10 years: -77.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Employees: 267

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

3% more funds holding

Funds holding: 194 [Q2] → 199 (+5) [Q3]

6% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 67

3% less call options, than puts

Call options by funds: $17.4M | Put options by funds: $17.9M

2.87% less ownership

Funds ownership: 62.75% [Q2] → 59.88% (-2.87%) [Q3]

11% less capital invested

Capital invested by funds: $1.09B [Q2] → $971M (-$117M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5.50 19% upside
• Avg. target: $7.75 67% upside
• High target: $10 116% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 50% 1-year accuracy 74 / 148 met price target	19% upside $5.50	Neutral Downgraded	11 Nov 2024
Citigroup Yigal Nochomovitz 22% 1-year accuracy 10 / 46 met price target	116% upside $10	Buy Maintained	4 Nov 2024